Collaboratories
The Nebraska Nanomedicine Production Plant is actively collaborating with academic and pharmaceutical industry programs. Currently, plant projects are ongoing with Exavir Therapeutics and ProTransit Nanotherapy.
Exavir Therapeutics
Drs. Howard Gendelman, Benson Edagwa and Mr. Alborz Yazdi are the cofounders of Exavir Therapeutics. This startup company was founded with the mission of putting an end to HIV. These three founders have a vastknowledge of HIV and other chronic disorders that spans many years along with multiple disciplines fromacademic research to biopharmaceutical industrial experience. The company is focused on Ultra-Long-Acting Therapeutics, targeting HIV integrase and a CRISPR-based cure for HIV. These methods are producing products that will be scaled up to be used in clinical trials.
The Nebraska Nanomedicine Production Plant provides vital product validation to Exavir Therapeutics. Exavir will uses plant equipment and resources necessary for large-scale nanoparticle production, accelerating production and testing for these pending clinical trials.
Learn more about Exavir Therapeutics
ProTransit Nanotherapy
Gary Madsen, MD is the President and CEO of ProTransit Nanotherapy. This start up company, founded in April 2013, focuses on developing nanoparticles with broad applications. The company is working on a range of therapeutics for spinal cord injuries, strokes and traumatic brain injuries as well as for skincare and cosmetics. It is preparing to scale up nontoxic and biodegradable nanoparticles containing active antioxidant enzymes that eliminate damaging free radicals.
With that goal in mind, the Nebraska Nanomedicine Production Plant provides vital product validation to ProTransit Nanotherapy. ProTransit Nanotherapy uses plant equipment and resources necessary for large-scale nanoparticle production, accelerating production and testing for pending clinical trials.
With GMP production capabilities for nanoformulations, the plant is able to provide board resources to local and national pharmaceutical companies with interest in nanoformulations. Dr. Madsen expects other pharmaceutical companies will contact the plant and use its unique set of resources.
Learn more about ProTransit Nanotherapy
NeuralRegen
NeuralRegen was founded was Mr. Joel Alperson, Drs. Howard Gendelman and Carol Swarts and the Oehlerking Farm Family. NeuralRegen’s seeks advancements in the treatment for neurodegenerative disease by developing therapies which engage the body’s natural ability to restore itself. By combining breakthrough neuroscience, regenerative biology, and precision therapeutic development, the company makes recovery possible. The multidisciplinary teams which include a scientific advisory board of top fields scientists the company works at the intersection of research and real-world application—translating laboratory discoveries into meaningful clinical outcomes. From targeted regenerative therapies to data-driven recovery protocols, every innovation is built around one purpose: restoring function and improving the quality of life. NeuralRegen’s research focuses on biomarker detection, disease monitoring, and next-generation immune-based therapeutics to reduce the growing and significant disease burden for patients, families, and providers. The Nebraska Nanomedicine Production Plant provides vital product manufacture to NeuralRegen. NeuralRegen uses the UNMC facility for production of large-scale extracellular vesicles for production and pending clinical trials.